The MTNAP1 Knockout SK-HEP-1 Polyclonal Cells provide a ready-to-use CRISPR/Cas9-edited polyclonal knockout cell population with targeted disruption of the MTNAP1 gene in the SK-HEP-1 human liver adenocarcinoma epithelial cell line. Engineered through CRISPR/Cas9-mediated gene disruption, this model generates a heterogeneous pool of knockout cells that maintain the biological variability inherent to the host line. The polyclonal format is particularly advantageous for studies requiring population-averaged phenotypes, such as drug response profiling and apoptosis kinetics, as it avoids the confounding effects of clonal selection.
SK-HEP-1 cells were originally isolated from the ascites of a patient with liver adenocarcinoma and have become a standard in vitro model for hepatocellular carcinoma (HCC) research. They exhibit epithelial morphology and express key enzymes involved in hepatic drug metabolism, making them suitable for pharmacological and metabolic investigations. Their tumorigenic properties, together with the retention of liver-specific functions, provide a relevant cellular environment to study oncogenic signaling, apoptosis, and mitochondrial biology in a liver cancer context.
The MTNAP1 gene encodes a protein that mediates mitochondrial outer membrane permeabilization (MOMP), a decisive step in the intrinsic apoptosis pathway. MTNAP1 acts downstream of apoptotic stimuli, notably DNA damage and the tumor suppressor p53, and is subject to regulation by the BCL-2 family: anti-apoptotic members BCL-2 and BCL-xL suppress its activity, while pro-apoptotic BAX and BAK may interact with MTNAP1 to facilitate MOMP. Additionally, MTNAP1 engages the voltage-dependent anion channel VDAC at the outer membrane, promoting pore formation. Once MOMP occurs, cytochrome c is released from the intermembrane space into the cytosol, where it binds APAF-1 to form the apoptosome. This complex activates initiator caspase-9, which subsequently cleaves effector caspase-3, leading to the proteolytic cascade that executes apoptosis. Thus, MTNAP1 serves as a crucial integrator of upstream death signals, translating stress inputs into a commitment to cell death.
Disruption of MTNAP1 in the SK-HEP-1 background establishes a powerful model for investigating apoptotic dysregulation in hepatocellular carcinoma. As HCC frequently develops resistance to apoptosis, this knockout tool allows researchers to examine how loss of a key MOMP mediator affects cell survival, mitochondrial integrity, and drug sensitivity. For instance, the model can be employed to study sorafenib-induced apoptosis and to probe compensatory mechanisms mediated by other BCL-2 family proteins. It also enables dissection of mitochondrial dynamics and the interplay between intrinsic apoptosis and hepatocarcinogenesis, potentially uncovering novel therapeutic targets.
These polyclonal knockout cells are applicable to a suite of apoptosis and mitochondrial function assays. Western blotting can monitor MTNAP1 expression and cytochrome c release, while fluorometric caspase-3 activity assays provide quantitative readouts. Flow cytometry using Annexin V and propidium iodide distinguishes early and late apoptotic populations. Immunofluorescence with TMRE assesses mitochondrial membrane potential, and co-immunoprecipitation can map interactions among BCL-2 family members. Drug sensitivity assays, particularly with sorafenib, evaluate chemotherapeutic response. For technical specifications and ordering inquiries, please contact Ascent Research.
